Can I Take Green Tea Extract (EGCG) with Low-Dose Naltrexone?

The direct answer

Low-dose naltrexone (LDN) is compounded naltrexone hydrochloride, the same active molecule sold at full dose as ReVia (oral, for alcohol and opioid dependence) or Vivitrol (injectable), but prescribed off-label at roughly 1.5-4.5 mg instead of the FDA-approved 50 mg. Green tea extract supplements deliver concentrated epigallocatechin gallate (EGCG), the main catechin in Camellia sinensis. Naltrexone at its FDA-approved dose carries a boxed hepatotoxicity warning; EGCG at concentrated supplement doses has an independent, dose-dependent liver-injury signal recognized by EFSA. No published trial has tested naltrexone and EGCG together, at any dose, so nothing here should be read as evidence that the combination has been studied and found safe. The practical position most clinicians would take is: LDN's low systemic exposure makes a severe interaction unlikely, but "unlikely" is not "studied," and anyone combining the two should keep EGCG well under the 800 mg/day EFSA threshold, get baseline liver enzymes, and watch for symptoms.

What is established, what is plausible, and what is not established

Established: Full-dose naltrexone (50 mg) carries an FDA boxed warning for hepatocellular injury, based on data reviewed at the time of approval. EFSA's food-safety review has identified EGCG intakes at or above 800 mg/day from supplements as a hepatotoxicity concern, and case reports of green-tea-extract-associated liver injury exist in the medical literature. EGCG bioavailability is higher when taken fasted than with food.

Plausible but unproven: That LDN doses (1.5-4.5 mg) combined with moderate EGCG intake (under 400 mg/day) produce a meaningfully additive liver-injury risk compared with either agent alone. That high-dose EGCG's weak in vitro inhibition of CYP3A4 translates into a clinically relevant increase in naltrexone or 6-beta-naltrexol exposure in humans. Both are mechanistically reasonable given each agent's known pharmacology, but neither has been tested directly.

Not established: Any specific numeric risk (a percentage, an odds ratio, a fold-increase) for liver injury when LDN and EGCG are combined. No such number exists in the literature because no combination trial has been conducted. Any claim on this page or elsewhere stating an exact combined-risk figure should be treated as unverified until traced to a primary source.

The single most defensible statement this page can make, and the one worth remembering, is this: LDN and EGCG have not been studied together, each has an independent, dose-dependent hepatotoxicity signal at higher exposures, and the rational response is dose control and monitoring rather than either avoidance or reassurance.

Naltrexone, the liver, and why the LDN dose matters

Naltrexone is cleared mainly through non-CYP pathways (dihydrodiol dehydrogenase to 6-beta-naltrexol), with a secondary role for CYP3A4 in its metabolism. The FDA label for full-dose naltrexone (50 mg) carries a boxed warning describing dose-related hepatocellular injury risk, based on data at that dose level; this is a regulatory fact, not an inference. At LDN doses of 1.5-4.5 mg, systemic exposure is a fraction of the 50 mg dose, and isolated LDN-associated hepatotoxicity is rarely reported in the clinical literature on LDN use for conditions such as fibromyalgia or inflammatory bowel disease. That lower exposure is reassuring but does not mean the liver-injury mechanism is absent, only that it is less likely to be triggered by naltrexone alone at this dose.

EGCG and the liver: what the dose-response data actually show

A cup of brewed green tea provides roughly 50-100 mg of EGCG. Concentrated extract capsules commonly contain 200-800 mg per serving, so a single capsule can exceed what a person would get from several cups of tea, delivered as a bolus rather than spread across a beverage matrix. EFSA's food-safety review (2018) concluded that green tea supplements providing about 800 mg or more of EGCG per day are linked to a risk of liver damage, and noted that lower chronic doses are not risk-free, particularly in combination with other hepatic stressors. Case series in the pharmacovigilance and hepatology literature describe green-tea-extract-associated liver injury with a range of latency periods from weeks to several months, with a pattern resembling other botanical-agent drug-induced liver injury (hepatocellular or cholestatic). The exact case counts and latency ranges cited in various reviews vary by source and should be verified against the primary paper before being repeated as a precise figure.

Taking EGCG on an empty stomach raises peak plasma concentrations compared with taking it with food, based on pharmacokinetic studies in healthy volunteers; the exact multiple reported varies by study and dosing condition and should not be quoted as a single fixed number without checking the specific paper. The practical takeaway that is well supported: fasted dosing of concentrated EGCG produces a higher, faster peak than fed dosing, and that peak is thought to matter more for hepatic stress than average daily exposure.

Is there a CYP3A4 interaction with naltrexone?

Naltrexone and its active metabolite are partially cleared through CYP3A4, per the FDA prescribing information for the full-dose product. High-dose EGCG has shown weak inhibition of CYP3A4 in vitro, and separate human studies of green tea catechins have shown altered plasma concentrations of other CYP- or transporter-dependent drugs, though the direction and magnitude of these effects have varied across studies and substrates, which is itself informative: EGCG's drug-interaction behavior is not uniform across drugs, and it should not be assumed to generalize to naltrexone.

No published clinical pharmacokinetic study has examined EGCG combined with naltrexone specifically. Given naltrexone's low absolute exposure at LDN doses, a modest degree of CYP3A4 inhibition would be expected to have a small effect on already-low plasma levels. This is a reasoned inference from each drug's separate pharmacology, not a tested result, and it should be labeled as such when discussed with a patient.

Evidence-status interaction assessment

Who should not combine these without hepatology input

• Active hepatitis B or C infection, or any degree of cirrhosis
• Baseline ALT or AST above roughly 3 times the upper limit of normal
• Heavy or recent alcohol use
• Concurrent use of other agents with hepatotoxicity signals (examples include kava and high-dose niacin; this is not an exhaustive list, and a pharmacist should review the full medication and supplement list)
• Nonalcoholic fatty liver disease with elevated transaminases, or a personal or family history of idiosyncratic drug-induced liver injury, both of which warrant a lower threshold for caution rather than an automatic contraindication

A practical monitoring approach if both are used

This is a site-judgment framework built from the FDA naltrexone label's general monitoring language and EFSA's supplement guidance. It is not a validated clinical protocol and does not substitute for individualized advice from the prescriber.

Before starting:

1. Baseline liver panel (ALT, AST, alkaline phosphatase, bilirubin).
2. Confirm the actual EGCG content of the product. Many "green tea extract" labels report total catechins or total polyphenols, not EGCG specifically; ask the patient to bring the label or check the supplement facts panel.
3. Take EGCG with food, not fasted, given the peak-concentration effect described above.
4. Review the full medication and supplement list for other hepatic stressors.

During the first two months: recheck liver enzymes around four weeks if EGCG intake is in the 200-400 mg/day range alongside LDN. Stop EGCG (not LDN, unless the prescriber advises otherwise) and contact the prescriber the same day for right upper quadrant discomfort, jaundice, dark urine, or unexplained fatigue. An ALT or AST rise above roughly three times the upper limit of normal warrants stopping EGCG and urgent evaluation.

Ongoing: if enzymes stay normal at eight weeks, quarterly rechecks are a reasonable, conservative approach for continued combined use, consistent with the general spirit of periodic liver-function monitoring described in the naltrexone label.

Does spacing the doses apart help?

Taking EGCG and LDN at different times of day reduces the window in which both are circulating in the blood at the same time, but the liver-injury concern here is pharmacodynamic, not a moment-to-moment interaction. Hepatocyte oxidative stress is thought to reflect cumulative daily exposure rather than simultaneous blood levels, so separating doses by a few hours does not resolve the shared hepatotoxicity concern. Taking EGCG with a midday meal (to reduce the fasted-state concentration peak) while keeping LDN at bedtime as prescribed is a reasonable, low-cost practice, but it is a modest risk-reduction step, not a fix that makes a high EGCG dose safe.

Why stacking may not add the benefit patients expect

People using LDN for fibromyalgia or autoimmune conditions often reach for EGCG because both are promoted for anti-inflammatory effects, LDN through a proposed rebound increase in endogenous opioid peptides that modulates microglial cytokine release, EGCG through effects on NF-kB and related inflammatory signaling pathways in laboratory models. These mechanisms partially overlap. A small placebo-controlled crossover trial has reported that LDN reduced fibromyalgia pain scores compared with placebo over about 12 weeks; the exact magnitude of that effect should be checked against the original trial report before being quoted as a specific number. No clinical trial has tested whether adding EGCG to LDN produces an additive anti-inflammatory benefit. Given the mechanistic overlap, it is plausible that combining the two adds more hepatic risk than incremental anti-inflammatory benefit, which is a reason to discuss the added value of EGCG with a prescriber rather than assuming more is better.

Practical guidance

Brewed green tea (roughly 2-4 cups/day, providing on the order of 100-300 mg EGCG total) has not shown a meaningful hepatotoxicity signal in healthy adults and is a lower-risk way to get green tea's polyphenol exposure than a concentrated extract capsule.

If a supplement is preferred, keeping EGCG under 400 mg/day, taken with food, with a baseline liver panel and a four-week recheck, is a conservative approach consistent with the safety margins described above, though it is a general recommendation and not a substitute for individualized guidance from the prescriber managing the LDN.

Do not combine EGCG doses at or above the EFSA-flagged 800 mg/day range with LDN without direct discussion with a physician or pharmacist, ideally with more frequent liver monitoring than described here.

Any of the following warrant contacting a clinician promptly rather than waiting for a scheduled recheck: right upper quadrant pain, jaundice, dark urine, unusual fatigue, or unexplained nausea.